Skip to main content
Advertisement
Advertisement

SUPN

SUPN logo

Supernus Pharmaceuticals, Inc.

43.83
USD
Sponsored
+0.08
+0.18%
Sep 23, 11:28 UTC -4
Open

SUPN Earnings Reports

Positive Surprise Ratio

SUPN beat 32 of 43 last estimates.

74%

Next Report

Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$224.63M
/
$0.62
Implied change from Q2 26 (Revenue/ EPS)
+2.54%
/
+16.98%
Implied change from Q3 25 (Revenue/ EPS)
+16.93%
/
-38.61%

Supernus Pharmaceuticals, Inc. earnings per share and revenue

On Aug 03, 2026, SUPN reported earnings of 0.53 USD per share (EPS) for Q2 26, beating the estimate of 0.42 USD, resulting in a 23.72% surprise. Revenue reached 219.06 million, compared to an expected 209.06 million, with a 4.78% difference. The market reacted with a +8.46% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of 0.62 USD, with revenue projected to reach 224.63 million USD, implying an increase of 16.98% EPS, and increase of 2.54% in Revenue from the last quarter.
FAQ
For Q2 2026, Supernus Pharmaceuticals, Inc. reported EPS of $0.53, beating estimates by 23.72%, and revenue of $219.06M, 4.78% above expectations.
The stock price moved up 8.46%, changed from $43.25 before the earnings release to $46.91 the day after.
The next earning report is scheduled for Nov 02, 2026.
Based on 6 analysts, Supernus Pharmaceuticals, Inc. is expected to report EPS of $0.62 and revenue of $224.63M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement